Refanezumab

Cat. No.:	HY-P99403
CAS No.:	1233953-61-1
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke[1][2].

In Vivo

Refanezumab (GSK249320; 10 mg/kg; IV; starting 24 hours post-stroke and continuing weekly for 6 more doses) shows larger increases in neuroscore and staircase test. Refanezumab by intravenous penetrates the lesion site and is associated with a small effect on functional outcomes when initiated 24 hours post-stroke[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague Dawley rats (weight 361g)[1]
Dosage:	10 mg/kg
Administration:	IV; starting 24 hours post-stroke and continuing weekly for 6 more doses; starting seven days post-stroke and continuing weekly for 5 more doses
Result:	Animals treated 24 hours post-stroke showed larger increases in neuroscore and staircase test as compared to controls, but animals treated 7 days post-stroke showed no significant behavioral benefit.

REFERENCES

[1]. Diana Cash, et al. GSK249320, A Monoclonal Antibody Against the Axon Outgrowth Inhibition Molecule Myelin-Associated Glycoprotein, Improves Outcome of Rodents with Experimental Stroke. J Neurol Exp Neurosci. 2016;2(2):28-33. Epub 2016 Nov 21.

[2]. B Abila, et al. First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers. Clin Pharmacol Ther. 2013 Feb;93(2):163-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA